Literature DB >> 25398697

Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Julie L Eiseman1, Jan H Beumer, Lora H Rigatti, Sandra Strychor, Kelly Meyers, Samuel Dienel, Charles C Horn.   

Abstract

PURPOSE: Cisplatin induces nausea and emesis, even with antiemetic supportive care. To assess platinum exposure, which could activate nausea and emesis, we quantitated platinum in the brain and various organs, and hindbrain and spinal cord substance P, a key neuropeptide for the neuronal signaling of nausea and emesis.
METHODS: Musk shrews, a model species for nausea and emesis research, were dosed intraperitoneally with 20 mg/kg cisplatin and euthanized at up to 72 h after injection. Concentrations of platinum were quantitated in plasma ultrafiltrate, plasma, lung, kidney, combined forebrain and midbrain, hindbrain, and spinal cord by flameless atomic absorption spectrometry. Hindbrains and spinal cords were analyzed for substance P by immunohistochemistry after injection of 20 or 30 mg/kg.
RESULTS: Plasma ultrafilterable platinum concentrations decreased rapidly till 60 min after dosing and then more slowly by 24 h. The concentrations of total platinum in both the fore- and midbrain and the hindbrain were similar at all time points and were at least 20-fold lower than plasma total platinum concentrations. There were no significant changes in substance P immunoreactivity after cisplatin dosing. Histology revealed damage to the renal cortex by 72 h after injection of cisplatin.
CONCLUSIONS: This is the first study to examine platinum concentrations in musk shrews after administration of cisplatin and delineate substance P immunohistochemical staining in the hindbrain and spinal cord of this species. The platinum concentrations detected in the brain could potentially contribute to the neurological side effects of cisplatin, such as nausea and emesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25398697      PMCID: PMC4282608          DOI: 10.1007/s00280-014-2623-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  41 in total

1.  In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion.

Authors:  Heidi Colville; Ryan Dzadony; Rebecca Kemp; Stephen Stewart; Herbert J Zeh; David L Bartlett; Julianne Holleran; Kevin Schombert; Juliann E Kosovec; Merrill J Egorin; Jan H Beumer
Journal:  J Extra Corpor Technol       Date:  2010-03

2.  Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: enkephalin and substance P.

Authors:  T Hökfelt; A Ljungdahl; L Terenius; R Elde; G Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

3.  Effect of time of cisplatin administration on its toxicity and pharmacokinetics in dogs.

Authors:  E M Hardie; R L Page; P L Williams; W D Fischer
Journal:  Am J Vet Res       Date:  1991-11       Impact factor: 1.156

4.  Computerized detection and analysis of cancer chemotherapy-induced emesis in a small animal model, musk shrew.

Authors:  Dong Huang; Kelly Meyers; Séverine Henry; Fernando De la Torre; Charles C Horn
Journal:  J Neurosci Methods       Date:  2011-03-15       Impact factor: 2.390

5.  Immunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in area postrema and medial nucleus tractus solitarius of rat brain.

Authors:  D M Armstrong; V M Pickel; T H Joh; D J Reis; R J Miller
Journal:  J Comp Neurol       Date:  1981-03-01       Impact factor: 3.215

Review 6.  Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.

Authors:  Masaru Minami; Toru Endo; Masahiko Hirafuji; Naoya Hamaue; Yanxia Liu; Tsutomu Hiroshige; Masahiro Nemoto; Hideya Saito; Mitsuhiro Yoshioka
Journal:  Pharmacol Ther       Date:  2003-08       Impact factor: 12.310

7.  Cisplatin-induced hearing loss does not correlate with intracellular platinum concentration.

Authors:  R Ramírez-Camacho; D Esteban Fernández; J M Verdaguer; M M Gómez Gómez; A Trinidad; J R García-Berrocal; M A Palacios Corvillo
Journal:  Acta Otolaryngol       Date:  2008-05       Impact factor: 1.494

8.  Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.

Authors:  D Esteban-Fernández; J M Verdaguer; R Ramírez-Camacho; M A Palacios; M M Gómez-Gómez
Journal:  J Anal Toxicol       Date:  2008-03       Impact factor: 3.367

9.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

10.  Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.

Authors:  A Johnsson; C Olsson; O Nygren; M Nilsson; B Seiving; E Cavallin-Stahl
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more
  6 in total

1.  Estimation of body surface area in the musk shrew ( Suncus murinus): a small animal for testing chemotherapy-induced emesis.

Authors:  Julie L Eiseman; Michael Sciullo; Hong Wang; Jan H Beumer; Charles C Horn
Journal:  Lab Anim       Date:  2017-02-26       Impact factor: 2.471

Review 2.  Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.

Authors:  Nathan B Roberts; Aniket S Wadajkar; Jeffrey A Winkles; Eduardo Davila; Anthony J Kim; Graeme F Woodworth
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

3.  Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.

Authors:  Denis V Navolotskii; Natalya B Ivanenko; Nikolay D Solovyev; Elena I Fedoros; Andrey V Panchenko
Journal:  Drug Test Anal       Date:  2015-06-10       Impact factor: 3.345

Review 4.  Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

Authors:  Daniel Ruiz-Molina; Xiaoman Mao; Paula Alfonso-Triguero; Julia Lorenzo; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Fernando Novio
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

5.  Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma.

Authors:  Gan Qiao; Huanli Xu; Cong Li; Xiao Li; Ammad Ahmad Farooqi; Yuming Zhao; Xiaohui Liu; Ming Liu; Dimitrios Stagos; Xiukun Lin
Journal:  Int J Mol Sci       Date:  2018-10-07       Impact factor: 5.923

6.  Efficacy and Safety of Human Serum Albumin-Cisplatin Complex in U87MG Xenograft Mouse Models.

Authors:  Cho Rong Park; Hyo Young Kim; Myung Geun Song; Yun-Sang Lee; Hyewon Youn; June-Key Chung; Gi Jeong Cheon; Keon Wook Kang
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.